Esperion Acquires Corstasis, Launches First FDA-Approved Nasal Diuretic
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy ESPR?
Source: Newsfilter
- Strategic Acquisition: Esperion is acquiring Corstasis for $75 million in cash, with Corstasis's Enbumyst™ being the first FDA-approved nasal diuretic, which is expected to significantly enhance Esperion's market position in cardiovascular care.
- Market Potential: Enbumyst targets 6.7 million American adults with heart failure, with a potential U.S. market opportunity exceeding $4 billion, addressing the growing medical needs and driving long-term revenue growth for Esperion.
- Innovative Treatment: Enbumyst offers self-administered outpatient diuretic therapy, bridging the gap between oral and IV treatments, which is expected to improve patient quality of life and reduce hospitalization rates.
- Future Outlook: Esperion plans to integrate Enbumyst into its existing commercial platform to drive sustained double-digit growth, further realizing its Vision 2040 and creating lasting value for patients and shareholders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ESPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ESPR
Wall Street analysts forecast ESPR stock price to rise
5 Analyst Rating
4 Buy
0 Hold
1 Sell
Moderate Buy
Current: 2.910
Low
1.72
Averages
7.94
High
16.00
Current: 2.910
Low
1.72
Averages
7.94
High
16.00
About ESPR
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Esperion Acquires Corstasis to Expand Product Line
- Acquisition Agreement Details: Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics, which includes a $75 million upfront cash payment and potential royalties and milestone payments totaling up to $180 million, indicating a proactive approach to expanding its product portfolio.
- Market Opportunity Analysis: The acquisition aims to leverage Esperion's established cardiovascular commercial infrastructure, targeting a market opportunity exceeding $4 billion in the U.S., and is expected to drive double-digit revenue growth, enhancing its leadership position in cardiovascular care.
- Financial Structure and Financing: Esperion plans to finance the acquisition through its existing credit facilities and royalty monetization of its Japanese royalties managed by Athyrium Capital Management and HealthCare Royalty, demonstrating flexibility and foresight in its financial operations.
- Stock Performance and Analyst Outlook: Following the acquisition announcement, Esperion's stock fell 5.4% in premarket trading to $3.09, reflecting market caution regarding the deal, while analysts maintain an optimistic outlook on future earnings expectations.
See More
Esperion Acquires Corstasis for $75M to Enhance Cardiovascular Treatment
- Acquisition Overview: Esperion has agreed to acquire all outstanding shares of Corstasis Therapeutics for an upfront payment of $75 million, with the transaction expected to close in Q2 2026, subject to customary closing conditions, indicating Esperion's intent to expand in the biopharmaceutical sector.
- Product Integration Potential: Corstasis's lead product, Enbumyst, received FDA approval in September 2025 as the first nasal diuretic for treating edema associated with congestive heart failure and liver and kidney diseases, and Esperion plans to integrate it into its existing commercial platform to drive sustained double-digit growth.
- Strategic Importance: CEO Sheldon Koenig emphasized that this acquisition not only accelerates the company's momentum but also strengthens its leadership in cardiovascular care, creating lasting value for patients, providers, and shareholders alike.
- Potential Earnings: Under the agreement, Corstasis shareholders are eligible for up to an additional $180 million upon achieving certain regulatory and commercial milestones, along with low double-digit royalties on sales of Enbumyst and follow-on products, enhancing the attractiveness of the deal.
See More
Esperion Acquires Corstasis, Launches First FDA-Approved Nasal Diuretic
- Strategic Acquisition: Esperion is acquiring Corstasis for $75 million in cash, with Corstasis's Enbumyst™ being the first FDA-approved nasal diuretic, which is expected to significantly enhance Esperion's market position in cardiovascular care.
- Market Potential: Enbumyst targets 6.7 million American adults with heart failure, with a potential U.S. market opportunity exceeding $4 billion, addressing the growing medical needs and driving long-term revenue growth for Esperion.
- Innovative Treatment: Enbumyst offers self-administered outpatient diuretic therapy, bridging the gap between oral and IV treatments, which is expected to improve patient quality of life and reduce hospitalization rates.
- Future Outlook: Esperion plans to integrate Enbumyst into its existing commercial platform to drive sustained double-digit growth, further realizing its Vision 2040 and creating lasting value for patients and shareholders.
See More
Esperion Grants Restricted Stock Units to New Employees
- Employee Incentive Program: On February 10, 2026, Esperion granted 40,200 restricted stock units (RSUs) to 11 new employees, aimed at attracting talent and enhancing employee loyalty, thereby improving overall company competitiveness.
- Grant Conditions Explained: Under the 2017 Inducement Equity Incentive Plan, RSUs will vest 25% on the one-year anniversary of the grant, with the remaining 75% vesting in twelve equal quarterly installments, ensuring employees remain with the company to realize full benefits.
- Company Background: Esperion is a commercial-stage biopharmaceutical company focused on developing innovative therapies for cardiometabolic and rare diseases, currently marketing two oral, non-statin therapies to help patients manage low-density lipoprotein cholesterol (LDL-C) levels.
- Market Positioning: With a broad U.S. commercial infrastructure and global approvals in over 40 countries, Esperion aims to be the partner of choice for global innovators seeking U.S. market access, driving future growth and market share expansion.
See More
Esperion Therapeutics Reports Strong 2025 Preliminary Results with $400 Million Revenue
- Significant Revenue Growth: Esperion's preliminary total revenue for 2025 reached $400 million to $408 million, reflecting a year-over-year increase of 20% to 23%, indicating strong market demand and product acceptance in the cardiovascular treatment sector.
- Strong Product Sales: The company's U.S. net product sales for NEXLETOL and NEXLIZET are projected to be between $156 million and $160 million, representing a 35% to 38% increase compared to 2024, showcasing expanded physician adoption and reimbursement coverage.
- Enhanced Financial Flexibility: As of year-end 2025, Esperion reported approximately $168 million in cash and cash equivalents, providing financial support for ongoing commercial expansion and pipeline development, ensuring sustainable future growth.
- Long-Term Strategic Planning: Esperion introduced its “Vision 2040” strategy aimed at evolving into a multi-product, innovation-driven global pharmaceutical company focused on cardiometabolic disease prevention and expansion into rare hepatic and renal indications, demonstrating the company's ambitious future development plans.
See More
Esperion Reports $156-$160 Million in 2025 Sales, Unveils Vision 2040 Strategy
- Significant Sales Growth: Esperion anticipates U.S. net product sales for 2025 to be between $156 million and $160 million, reflecting a 35% to 38% increase compared to 2024, indicating strong performance and demand in the cardiovascular sector.
- Optimistic Revenue Outlook: The company expects total revenue to range from $400 million to $408 million in 2025, representing a 20% to 23% increase from 2024, showcasing success in product portfolio expansion and market penetration.
- Vision Strategy Unveiled: Esperion introduced its Vision 2040 strategy, aiming to evolve into a global leader in cardiovascular disease prevention with a diversified product portfolio and a robust pipeline, targeting at least five blockbuster products by 2040.
- Market Expansion Plans: The company plans to enhance its revenue opportunities in the cardiovascular prevention market by investing in sales and marketing, particularly through the introduction of two triple combination products, which are expected to significantly boost competitive positioning.
See More
Esperion Acquires Corstasis to Expand Product Line
- Acquisition Agreement Details: Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics, which includes a $75 million upfront cash payment and potential royalties and milestone payments totaling up to $180 million, indicating a proactive approach to expanding its product portfolio.
- Market Opportunity Analysis: The acquisition aims to leverage Esperion's established cardiovascular commercial infrastructure, targeting a market opportunity exceeding $4 billion in the U.S., and is expected to drive double-digit revenue growth, enhancing its leadership position in cardiovascular care.
- Financial Structure and Financing: Esperion plans to finance the acquisition through its existing credit facilities and royalty monetization of its Japanese royalties managed by Athyrium Capital Management and HealthCare Royalty, demonstrating flexibility and foresight in its financial operations.
- Stock Performance and Analyst Outlook: Following the acquisition announcement, Esperion's stock fell 5.4% in premarket trading to $3.09, reflecting market caution regarding the deal, while analysts maintain an optimistic outlook on future earnings expectations.
See More
Esperion Acquires Corstasis for $75M to Enhance Cardiovascular Treatment
- Acquisition Overview: Esperion has agreed to acquire all outstanding shares of Corstasis Therapeutics for an upfront payment of $75 million, with the transaction expected to close in Q2 2026, subject to customary closing conditions, indicating Esperion's intent to expand in the biopharmaceutical sector.
- Product Integration Potential: Corstasis's lead product, Enbumyst, received FDA approval in September 2025 as the first nasal diuretic for treating edema associated with congestive heart failure and liver and kidney diseases, and Esperion plans to integrate it into its existing commercial platform to drive sustained double-digit growth.
- Strategic Importance: CEO Sheldon Koenig emphasized that this acquisition not only accelerates the company's momentum but also strengthens its leadership in cardiovascular care, creating lasting value for patients, providers, and shareholders alike.
- Potential Earnings: Under the agreement, Corstasis shareholders are eligible for up to an additional $180 million upon achieving certain regulatory and commercial milestones, along with low double-digit royalties on sales of Enbumyst and follow-on products, enhancing the attractiveness of the deal.
See More
Esperion Acquires Corstasis, Launches First FDA-Approved Nasal Diuretic
- Strategic Acquisition: Esperion is acquiring Corstasis for $75 million in cash, with Corstasis's Enbumyst™ being the first FDA-approved nasal diuretic, which is expected to significantly enhance Esperion's market position in cardiovascular care.
- Market Potential: Enbumyst targets 6.7 million American adults with heart failure, with a potential U.S. market opportunity exceeding $4 billion, addressing the growing medical needs and driving long-term revenue growth for Esperion.
- Innovative Treatment: Enbumyst offers self-administered outpatient diuretic therapy, bridging the gap between oral and IV treatments, which is expected to improve patient quality of life and reduce hospitalization rates.
- Future Outlook: Esperion plans to integrate Enbumyst into its existing commercial platform to drive sustained double-digit growth, further realizing its Vision 2040 and creating lasting value for patients and shareholders.
See More
Esperion Grants Restricted Stock Units to New Employees
- Employee Incentive Program: On February 10, 2026, Esperion granted 40,200 restricted stock units (RSUs) to 11 new employees, aimed at attracting talent and enhancing employee loyalty, thereby improving overall company competitiveness.
- Grant Conditions Explained: Under the 2017 Inducement Equity Incentive Plan, RSUs will vest 25% on the one-year anniversary of the grant, with the remaining 75% vesting in twelve equal quarterly installments, ensuring employees remain with the company to realize full benefits.
- Company Background: Esperion is a commercial-stage biopharmaceutical company focused on developing innovative therapies for cardiometabolic and rare diseases, currently marketing two oral, non-statin therapies to help patients manage low-density lipoprotein cholesterol (LDL-C) levels.
- Market Positioning: With a broad U.S. commercial infrastructure and global approvals in over 40 countries, Esperion aims to be the partner of choice for global innovators seeking U.S. market access, driving future growth and market share expansion.
See More
Esperion Therapeutics Reports Strong 2025 Preliminary Results with $400 Million Revenue
- Significant Revenue Growth: Esperion's preliminary total revenue for 2025 reached $400 million to $408 million, reflecting a year-over-year increase of 20% to 23%, indicating strong market demand and product acceptance in the cardiovascular treatment sector.
- Strong Product Sales: The company's U.S. net product sales for NEXLETOL and NEXLIZET are projected to be between $156 million and $160 million, representing a 35% to 38% increase compared to 2024, showcasing expanded physician adoption and reimbursement coverage.
- Enhanced Financial Flexibility: As of year-end 2025, Esperion reported approximately $168 million in cash and cash equivalents, providing financial support for ongoing commercial expansion and pipeline development, ensuring sustainable future growth.
- Long-Term Strategic Planning: Esperion introduced its “Vision 2040” strategy aimed at evolving into a multi-product, innovation-driven global pharmaceutical company focused on cardiometabolic disease prevention and expansion into rare hepatic and renal indications, demonstrating the company's ambitious future development plans.
See More
Esperion Reports $156-$160 Million in 2025 Sales, Unveils Vision 2040 Strategy
- Significant Sales Growth: Esperion anticipates U.S. net product sales for 2025 to be between $156 million and $160 million, reflecting a 35% to 38% increase compared to 2024, indicating strong performance and demand in the cardiovascular sector.
- Optimistic Revenue Outlook: The company expects total revenue to range from $400 million to $408 million in 2025, representing a 20% to 23% increase from 2024, showcasing success in product portfolio expansion and market penetration.
- Vision Strategy Unveiled: Esperion introduced its Vision 2040 strategy, aiming to evolve into a global leader in cardiovascular disease prevention with a diversified product portfolio and a robust pipeline, targeting at least five blockbuster products by 2040.
- Market Expansion Plans: The company plans to enhance its revenue opportunities in the cardiovascular prevention market by investing in sales and marketing, particularly through the introduction of two triple combination products, which are expected to significantly boost competitive positioning.
See More
